A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
Targownik L, Pone E, Latour MG, Boyerahmadi K, Yang H, Ling J, Tehrani A, Golden S, Marshall JK
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.